|
Scott Minick is a Managing Director with ARCH, joining the firm as a Venture Partner in 1998. Mr. Minick has been instrumental in the startup, development and financing of numerous portfolio companies including XenoPort (XNPT), FastTrack Systems, MedVantx, Achaogen, BIND Biosciences Amphora Discovery, Celula, Ensemble Discovery, and Sorbent Therapeutics. He serves as a board director for Achaogen, Amphora Discovery, Celula, FastTrack Systems, Bind Biosciences, and Sorbent Therapeutics. Mr. Minick currently serves as Chairman of the Board for MedVantx and formerly served as Chairman of Xcyte Therapies (XCYT) through its IPO in 2004 and subsequent acquisition of Cyclacel Pharmaceuticals (CYCL). He also previously served as Executive Chairman of Amphora Discovery. From 1995 until 1998, Mr. Minick was director, President and COO of SEQUUS Pharmaceuticals, a public biopharmaceutical company that was acquired by GlaxoSmithKline. From 1994 to 1995, he served as a director, President and CEO of OncoTherapeutics, a private biotechnology company. Prior to that, Mr. Minick co-founded and was a director, President and CEO of LXR Biotechnology from startup through its IPO. From 1981 to 1993, he was an executive of Baxter Healthcare, holding leadership positions in the device, service and diagnostics businesses. He received his postgraduate training in neurobiology at the Salk Institute, an M.B.A. from Northwestern University and a B.A. with Honors from the University of California at San Diego. | 